TAK-280 / Takeda - LARVOL DELTA

COBRA: First-in-Human Study of TAK-280 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=69 | Terminated | Sponsor: Takeda | Active, not recruiting ➔ Terminated; Terminated due to limited anti-cancer activity

Trial termination • Oncology • Solid Tumor

COBRA: First-in-Human Study of TAK-280 in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=69 | Active, not recruiting | Sponsor: Takeda | Recruiting ➔ Active, not recruiting | N=182 ➔ 69 | Trial completion date: Jul 2026 ➔ Jun 2025 | Trial primary completion date: Feb 2025 ➔ Jun 2025

Enrollment change • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors. (ASCO 2024) - P1/2 | "Cytokine release syndrome is closely managed and reported per American Society for Transplantation and Cellular Therapy consensus grading. Approximately 182 patients are planned to be enrolled (42 in dose escalation and 100–142 in cohort-expansion); as of the data cutoff date of Jan 10, 2024, 18 patients have received the study drug."

Clinical • Metastases • P1/2 data • Gastroenterology • Gastrointestinal Disorder • Genito-urinary Cancer • Immunology • Lung Cancer • Metastatic Castration-Resistant Prostate Cancer • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Solid Tumor • CD276

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - P1/2 | N=186 | Recruiting | Sponsor: Takeda | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

First-in-Human Study of TAK-280 in Participants With Unresectable Locally Advanced or Metastatic Cancer (clinicaltrials.gov) - P1/2 | N=186 | Not yet recruiting | Sponsor: Takeda

New P1/2 trial • Oncology • Solid Tumor

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel Immuno-Oncology Portfolio (Businesswire) - “Takeda Pharmaceutical Company Limited…announced the exercise of its option to acquire Maverick Therapeutics, Inc…Under the agreement, Takeda will obtain Maverick’s T-cell engager COBRA™ platform and a broad development portfolio, including Maverick’s lead development candidate TAK-186 (MVC-101) currently in a Phase 1/2 study for the treatment of EGFR-expressing solid tumors, and TAK-280 (MVC-280), which is anticipated to enter the clinic in the second half of Takeda’s fiscal year 2021 for the treatment of patients with B7H3-expressing solid tumors…Takeda exercised its option to acquire Maverick for a pre-negotiated upfront payment as well as potential development and regulatory milestones totaling up to $525 million…The deal is expected to be finalized in Q1 of Takeda’s fiscal year 2021.”

M&A • Oncology • Solid Tumor